Search | Clinical Trials Finder

Conditions: Lymphoma, T-Cell Lymphoma, Cutaneous Lymphoma
Interventions: Istodax, Doxil; Drug
Lead sponsor: Weiyun Ai; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Glioma, Brain Tumor, Primary
Interventions: CogMed®; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Covid19, Coronavirus, SARS-CoV 2
Interventions: QuadraMune(TM); Dietary Supplement
Lead sponsor: Therapeutic Solutions International; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Oceanside, California

Conditions: Cancer
Interventions: cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: HIV Infections
Interventions: HIV-1 DNA vaccine with protein vaccine boost; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Sjögren's Disease
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: Neoplasms, Lymphoma
Interventions: MLN9708, Nelfinavir; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 832 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 43
States / cities: Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more

Conditions: Hairy Cell Leukemia
Interventions: Cladribine, Rituximab, BMbx, MRI, EKG, Echocardiogram, Abdominal/splenic ultrasound, Stress test; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 1 Diabetes, Pregnancy, High Risk, Insulin Dependent Diabetes, Pregnancy Related
Interventions: Commercial AID system, Open source AID system; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Chembio Diagnostic Systems, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Asthma
Interventions: Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 25
States / cities: Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more

Conditions: Acute T-Cell Leukemia-Lymphoma
Interventions: Alemtuzumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Refractory Cutaneous T-cell Lymphoma
Interventions: Bexarotene; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 14 more

Conditions: Asthma
Interventions: fenoTRACK Device; Device
Lead sponsor: Biometry Inc; Industry
Eligibility: 5 Years to 100 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Stockton, California • Panama City, Florida • Columbus, Georgia + 10 more

Conditions: Hepatic Insufficiency
Interventions: Alisporivir; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Multiple Myeloma
Interventions: Siltuximab, Bortezomib, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 11
States / cities: Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Non-Hodgkin Lymphoma
Interventions: SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
Interventions: IMGN529; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 3 more

Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
Interventions: Rituximab, Etoposide, Siplizumab, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 12 Years to 21 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infections
Interventions: PGT121.414.LS, VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 2 more

Conditions: Chronic Fatigue Syndrome
Interventions: Placebo, Sodium Oxybate; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory

QuadraMune(TM) for Prevention of COVID-19

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Commercial or Open Source Closed Loop Impact on Pregnancy Study

Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Children With Diabetes at Risk for Heart Disease.

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome